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The largest worldwide population screening for
cancer family syndromes was initiated in January 2001
in the West Pomeranian Region of Poland with 1.7 m
inhabitants. In the first step in the period January 2001
– May 2002 family doctors and nurses collected
questionnaires asking about cancer family history
among 1st and 2nd degree relatives from 1,258,401
of 1.5 m individuals (87%) who were insured in the
West Pomeranian Regional Health Foundation. Up to
now about 1.15 m questionnaires have been evaluated
by geneticists/oncologists. According to questionnaire
data around 2% of families fulfilled criteria to be
suspected for cancer family syndrome. Family members
(usually 1-2 representatives per family) from suspected
families were invited for detailed examination. After
pedigree and clinical examination as well as DNA/RNA
analyses, high genetic predisposition to neoplasms was
diagnosed in 10,525 families. Diagnosis of the
following syndromes was established definitively or with
high probability:
1. Hereditary breast/ovarian cancer syndrome – 4121
families including 438 families with diagnosed
BRCA1/2 mutation.
2. Familial syndromes of colorectal cancer:
a) HNPCC – 568 families including 63 families with
diagnosed MSH2/MLH1 mutation,
b) FAP – 22 families,
c) Late onset colorectal cancer aggregations – 459
families.
3. Other hereditary organ specific syndromes:
a) hereditary stomach cancer – 1250 families,
b) hereditary renal cancer – 565 families,
c) hereditary laryngeal cancer – 206 families,
d) hereditary prostate cancer – 170 families,
e) NFI – 66 families,
f) VHL – 36 families,
g) Retinoblastoma – 4 families,
h) Peutz Jeghers syndrome – 3 families,
i) juvenile polyposis – 2 families.
4. Organ-specific familial aggregations:
a) familial lung cancer – 242 families,
b) familial leukaemia/lymphoma – 77 families,
c) familial liver cancer – 68 families,
d) familial cervical cancer – 30 families,
e) familial pancreatic cancer – 73 families,
f) familial melanoma – 44 families,
g) familial bladder – 19 families.
5. Unspecified cancer family aggregations – 3319
families.
Appropriate management has been introduced in
all identified families with high predisposition to
malignancies. 
